Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is positioning itself at the intersection of artificial intelligence and precision medicine, aiming to transform the early detection and diagnosis of coronary heart disease. The company's blood-based tests, Epi+Gen CHD and PrecisionCHD, leverage a proprietary AI-driven Multi-Omics Engine that analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including nonobstructive forms that conventional methods may miss.
The cardiovascular disease market is substantial and growing, with annual healthcare costs projected to increase from $393 billion in 2020 to $1.4 trillion by 2050. Cardio Diagnostics' tests address a critical gap in current diagnostics, potentially reducing costs and improving outcomes through earlier intervention. The company has strengthened its commercialization efforts by securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanding provider partnerships in the U.S., and launching its first international expansion in India.
Cardio Diagnostics' platform is built on a foundation of epigenetics and genetics, combined with artificial intelligence to provide insights that traditional diagnostic tools may overlook. The company's approach is clinically validated and commercially actionable, with growing provider adoption and evidence supporting its ability to detect coronary heart disease early. As the company continues to expand its reach and solidify reimbursement pathways, it occupies a unique position in the diagnostics landscape.
For more information, visit the company's website at https://cdio.ai/ or view the full article at https://nnw.fm/9LJ2r.
NetworkNewsWire is a communications platform focused on financial news and content distribution. For more details, visit https://www.NetworkNewsWire.com.
